Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CVGENES-AT-TARGET

Financiado

Cerrado

Exploitation of genomic variants affecting coronary artery disease and stroke ri...

Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effec... ver más

31/03/2017

EIT Urban Mobility...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

EIT URBAN MOBILITY INNOVATION HUB C No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-03-31 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

EIT Urban Mobility Innovatio...

0.00€ | Lider

ULEIC

N.D. | Participante

UZL

N.D. | Participante

Start Codon Limited

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CARDIOPREVENT INTEGRATION OF GENOMICS AND CARDIOMETABOLIC PLASMA BIOMARKER... 2M€ Cerrado

SECRET Single cEll guided polygeniC Risk prEdicTion of ASCVD 2M€ Cerrado

CoMorMent Predicting comorbid cardiovascular disease in individuals wi... 6M€ Cerrado

MIRACLE MultiomIcs based Risk stratification of Atherosclerotic Card... 4M€ Cerrado

Sex Dimorphism Molecular circuits of sex dimorphism in cardiometabolic trai... 173K€ Cerrado

UCARE Uncovering the epigenetic signature of female specifiC biolo... 2M€ Cerrado

Líder del proyecto

EIT URBAN MOBILITY INNOVATION HUB C No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors. More recently, results of genome-wide association (GWA) studies added to our perception of mechanisms leading to atherosclerosis. At present, over 40 CAD and several genomic risk loci have been identified, the majority through efforts led by the applicants. Some genes at these loci work through known risk factors such as lipids and, in fact, are already established or evolving treatment targets. However, this is not true for the majority of risk variants, which implies that key pathways leading to atherosclerosis are yet to be exploited for therapeutic intervention. This EU network (CVgenes@target), which brings together an equal number of SME- and academic partners, will utilize genomic variants affecting atherosclerosis risk for identification of both underlying genes and affected pathways in order to identify, characterize, and validate novel therapeutically relevant targets for prevention and treatment of CAD and stroke. In programme 1 we will investigate molecular mechanisms at the genomic loci in order to further unravel causal genes, in programme 2 we will explore in vitro and in vivo whether the pathways disturbed by causal genes are suitable for therapeutic intervention, and in programme 3 we will establish assays and initiate high throughput screens to tackle therapeutically attractive targets. Our resources including large OMICs and state-of-the-art bioinformatics platforms as well as multiple, already established in vitro and in vivo models support the feasibility of the approach. In fact, two genomic risk loci (ADAMTS7 (CAD); HDAC9 (stroke and CAD)), both identified in GWA studies under direction of the applicants, already revealed attractive targets for therapeutic intervention.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores